SCHEMBL6698066

SCHEMBL6698066

Cc1ccc(-c2nc(NC(=N)N)nc3cc(C)c(Cl)cc23)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 1/20 0.41
KDM4E B2RXH2 10/20 0.41
ALDH1A1 P00352 6/20 0.41
GAA P10253 4/20 0.41
KMT2A Q03164 3/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HPGD P15428 2/20 0.38
MAPK1 P28482 1/20 0.38
CASP1 P29466 1/20 0.38
RAB9A P51151 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 6/20 0.37
MEN1 O00255 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6695182 0.84 HSP90AB1 (0.61) HSP90AB1KDM4EALDH1A1GAAKMT2A
SCHEMBL6693939 0.80 GAA (0.51) KDM4EALDH1A1GAAKMT2ASMN1; SMN2
SCHEMBL6695082 0.80 KDM4E (0.46) HSP90AB1KDM4EALDH1A1GAAKMT2A
SCHEMBL6697410 0.79 MAPT (0.48) HSP90AB1KDM4EALDH1A1GAAKMT2A
SCHEMBL6701729 0.79 ADORA2A (0.57) KDM4EALDH1A1GAAKMT2ALMNA
SCHEMBL6696503 0.79 HSP90AB1 (0.41) HSP90AB1KDM4EALDH1A1GAAKMT2A
SCHEMBL6695246 0.78 KDM4E (0.65) KDM4EALDH1A1GAAKMT2ALMNA
SCHEMBL6695252 0.77 KDM4E (0.54) KDM4EALDH1A1GAAKMT2ALMNA
SCHEMBL6696127 0.76 MAPT (0.59) HSP90AB1KDM4EALDH1A1GAAKMT2A
SCHEMBL6698073 0.76 RAD52 (0.54) HSP90AB1KDM4EALDH1A1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224965-A1 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors MERCK PATENT GMBH (DE) 2004-11-11 US claimed
US-20040224965-A1 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors MERCK PATENT GMBH (DE) 2004-11-11 US disclosed
EP-1274691-A1 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS MERCK PATENT GmbH (DE) 2003-01-15 EP disclosed
WO-2001079186-A1 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS MERCK PATENT GMBH (DE) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224965-A1 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors NHERF1, SLC9A3, SLC9A1 HSP90AB1 1039/4885KDM4E 4437/4885ALDH1A1 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.